| Bayer (Schweiz) AG - NUBEQA 300 mg, Filmtabletten | | 67521 | | 01 | | NUBEQA 300 mg | | Filmtabletten | | L02BB06 | | Darolutamide | | 19.06.2020 | | |
| | Composition | | darolutamidum 300 mg, calcii hydrogenophosphas, carmellosum natricum conexum corresp. natrium 2.7 mg, lactosum monohydricum, magnesii stearas, povidonum K 30, Überzug: hypromellosum, lactosum monohydricum, macrogolum 3350, E 171, pro compresso obducto corresp. lactosum monohydricum 186 mg. | | Packungsbestandteile | | Coated tablets | | | | | Active Agent | Dose |
|---|
| Darolutamidum | 300 mg |
| | BAG: Active Agent | Dose |
|---|
| Darolutamidum | 300 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Calcium Hydrogen Phosphate | | | | Carmellosum Natricum Conexum | | | | E 171 | | color. | | Hypromellosum | | Überzug | | Lactose Monohydrate | | | | Macrogol | 3350 | | | Magnesii Stearas | | | | Povidonum K | 30 | | | Pro Compresso Obducto | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | 112 | 2930.21 | 3203.20 | B | SL | Yes |
|
|
